ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics
ScaleReady announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant in collaboration with Wilson Wolf Manufacturing and Bio-Techne (NASDAQ: TECH). The grant will support development of novel CAR γδ T cell therapies for autoimmune conditions. Luminary's approach combines Vδ1 and Vδ2 subsets with immune cloaking mechanism and utilizes Bio-Techne's TcBuster™ technology. The company claims their manufacturing process can produce 180-200 patient doses per run at less than $10,000 per drug product. The grant is part of ScaleReady's $20M initiative to advance cell and gene therapy development.
ScaleReady ha annunciato che Luminary Therapeutics è stata premiata con un grant G-Rex® di $300,000 in collaborazione con Wilson Wolf Manufacturing e Bio-Techne (NASDAQ: TECH). Il grant supporterà lo sviluppo di nuove terapie CAR γδ T cell per condizioni autoimmuni. L'approccio di Luminary combina i sottogruppi Vδ1 e Vδ2 con un meccanismo di camuffamento immune e utilizza la tecnologia TcBuster™ di Bio-Techne. L'azienda afferma che il loro processo di produzione può generare 180-200 dosi per paziente per ogni ciclo a meno di $10,000 per prodotto farmaceutico. Il grant è parte dell'iniziativa da $20M di ScaleReady per promuovere lo sviluppo della terapia cellulare e genica.
ScaleReady anunció que Luminary Therapeutics ha recibido una subvención G-Rex® de $300,000 en colaboración con Wilson Wolf Manufacturing y Bio-Techne (NASDAQ: TECH). La subvención apoyará el desarrollo de nuevas terapias con células T CAR γδ para condiciones autoinmunitarias. El enfoque de Luminary combina los subgrupos Vδ1 y Vδ2 con un mecanismo de enmascaramiento inmunológico y utiliza la tecnología TcBuster™ de Bio-Techne. La compañía afirma que su proceso de fabricación puede producir de 180 a 200 dosis por paciente por cada ciclo a menos de $10,000 por producto farmacéutico. La subvención es parte de la iniciativa de $20M de ScaleReady para avanzar en el desarrollo de terapias celulares y génicas.
ScaleReady는 Luminary Therapeutics가 Wilson Wolf Manufacturing 및 Bio-Techne (NASDAQ: TECH)와 협력하여 $300,000 G-Rex® Grant를 수상했다고 발표했습니다. 이 보조금은 자가면역 질환에 대한 새로운 CAR γδ T 세포 요법 개발을 지원할 것입니다. Luminary의 접근 방식은 Vδ1 및 Vδ2 하위 집합과 면역 은폐 메커니즘을 결합하고 Bio-Techne의 TcBuster™ 기술을 활용합니다. 이 회사는 그들의 제조 공정이 한 번의 생산으로 환자당 180-200회의 용량을 $10,000 미만의 비용으로 생산할 수 있다고 주장합니다. 이 보조금은 세포 및 유전자 치료 개발을 촉진하기 위한 ScaleReady의 $20M 이니셔티브의 일환입니다.
ScaleReady a annoncé que Luminary Therapeutics a reçu une subvention G-Rex® de 300 000 $ en collaboration avec Wilson Wolf Manufacturing et Bio-Techne (NASDAQ: TECH). Cette subvention soutiendra le développement de nouvelles thérapies par cellules T CAR γδ pour des maladies auto-immunes. L'approche de Luminary combine les sous-ensembles Vδ1 et Vδ2 avec un mécanisme de masquage immunitaire et utilise la technologie TcBuster™ de Bio-Techne. L'entreprise affirme que son processus de fabrication peut produire 180 à 200 doses par patient par cycle pour moins de 10 000 $ par produit pharmaceutique. Cette subvention fait partie de l'initiative de 20 millions de dollars de ScaleReady pour faire progresser le développement des thérapies cellulaires et géniques.
ScaleReady gab bekannt, dass Luminary Therapeutics einen G-Rex® Grant in Höhe von 300.000 $ in Zusammenarbeit mit Wilson Wolf Manufacturing und Bio-Techne (NASDAQ: TECH) erhalten hat. Der Grant unterstützt die Entwicklung neuartiger CAR γδ T-Zelltherapien für Autoimmunerkrankungen. Luminarys Ansatz kombiniert die Vδ1- und Vδ2-Untergruppen mit einem Mechanismus zur Immunschutz und nutzt die TcBuster™-Technologie von Bio-Techne. Das Unternehmen behauptet, dass ihr Produktionsprozess 180-200 Arzneimitteldosen pro Charge zu Kosten von weniger als 10.000 $ pro Arzneimittelprodukt produzieren kann. Der Grant ist Teil von ScaleReadys 20-Millionen-Dollar-Initiative zur Förderung der Entwicklung von Zell- und Gentherapien.
- Grant award of $300,000 for therapy development
- Cost-efficient manufacturing at less than $10,000 per drug product
- High production capacity of 180-200 patient doses per manufacturing run
- None.
Insights
The
The grant's impact extends beyond immediate research funding, as it enables optimization of multiple CAR γδ T cell therapies with enhanced safety features and functionality. The planned incorporation of safety switches and novel co-stimulatory domains strengthens the therapeutic profile. This development pipeline, leading to multiple IND applications, positions Bio-Techne favorably in the expanding cell therapy market.
This grant represents a strategic validation of Bio-Techne's TcBuster™ technology and strengthens its position in the cell therapy manufacturing space. The cost-effectiveness of Luminary's manufacturing process at
Luminary Therapeutics' CAR γδ T cell drug products contain a combination of the Vδ1 and Vδ2 subsets, a distinct approach from other developers of γδ T cell therapies, which Luminary anticipates providing improved cytotoxicity, greater adaptive capacity, and increased persistence. Luminary's technology also employs an "immune cloaking" mechanism to assist the γδ T cells in evading the host's immune system by reducing the expression of MHC class I/II on the surface of the γδ T cells. Finally, Luminary Therapeutics deploys Bio-Techne's novel transposition-based gene engineering technology called TcBuster™ which has fundamental advantages in the reduction of time and cost associated with clinical translation of a cell therapy drug product. Luminary has previously presented cost analysis indicating that their CAR γδ T cell therapies can yield 180-200 patient doses per manufacturing run at a manufacturing cost of less than
"Luminary is very grateful to be a beneficiary of the G-Rex Grant Program. The G-Rex Grant Program is a very creative, non-dilutive funding mechanism that aligns the interest of all stakeholders. It will directly impact our ability to generate the clinically significant data we need to attract the investment required to advance the state of our γδ T cell pipeline," says Mr. Jeff Liter, CEO of Luminary Therapeutics.
"We're happy to support Luminary Therapeutics with a G-Rex Grant. The program will accelerate the clinical use of Luminary's γδ T cell therapy program and this is yet another example of how the G-Rex Grant Program is saving time and money for recipients," said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex.
As part of the G-Rex Grant, Luminary will optimize several CAR γδ T cell therapies to enhance the resiliency, safety, and function of their CAR by incorporating safety switches, novel co-stimulatory domains, endogenous growth factor production, and MHC-I/II inhibitory elements. Large-scale, cGMP-compliant manufacturing will occur to support multiple Investigational New Drug (IND) applications that are estimated to be filed with the Food and Drug Administration (FDA) for the initiation of several Phase 1 clinical trials to evaluate the safety and efficacy of the several CAR γδ T cell therapies in a suite of autoimmune diseases.
ScaleReady's G-Rex Grant Program is a
For more information about the G-Rex® Grant Program, please contact info@scaleready.com.
About Luminary Therapeutics
Luminary Therapeutics is revolutionizing allogeneic CAR-T therapy by pioneering a triple receptor CAR design aimed at surpassing the efficacy of conventional single receptor CD19 treatments for autoimmune diseases. Additionally, our innovative split co-stimulatory CAR design is poised to propel the industry forward in addressing solid tumors. Currently, Luminary is conducting three Phase I First-in-Human trials utilizing an autologous format to establish safety and detect early indications of efficacy. Encouragingly, our second treated patient has already achieved a complete response (CR) without experiencing cytokine release syndrome (CRS). As we embark on the early stages of a Series A fundraising round, Luminary is committed to advancing our assets through the clinical trial pipeline, bringing hope and transformative therapies to patients in need.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics-302289750.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to Luminary Therapeutics through Bio-Techne (TECH)?
How many patient doses can Luminary Therapeutics produce per manufacturing run?
What is the total value of ScaleReady's G-Rex Grant Program associated with Bio-Techne (TECH)?
